All In Biotech

Drug Trial Radar · NCT04829604

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

72

Actual

Start

Oct 26, 2021

Primary completion

Dec 2026

Study completion Jun 2027

Sponsor

Lead sponsor
Ambrx, Inc.Industry
Sponsor type
Industry
First posted
Apr 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd

Conditions

  • HER2 Positive Metastatic Breast Cancer

Interventions

  • ARX788Drug

    The active pharmaceutical ingredient in ARX788 is an antibody drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two microtubule-disrupting payloads AS269

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: 2 years

Locations

33 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    San Francisco, California

  • Research Site

    Whittier, California

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Louisville, Kentucky

  • Research Site

    Silver Spring, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    St Louis, Missouri

  • Research Site

    Omaha, Nebraska

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Camden, New Jersey

  • Research Site

    New Hyde Park, New York

  • Research Site

    New York, New York

  • Research Site

    Shirley, New York

  • Research Site

    The Bronx, New York

  • Research Site

    Portland, Oregon

  • Research Site

    Tigard, Oregon

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Norfolk, Virginia

  • Research Site

    Tacoma, Washington

  • Research Site

    Frankston, Victoria, Australia

  • Research Site

    Geelong, Victoria, Australia

  • Research Site

    Nedlands, Western Australia, Australia

  • Research Site

    Daegu, South Korea

  • Research Site

    Seongnam-si, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.